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Up to 70% of adrenal masses detected in patients affected by extra-adrenal malignancy are metastatic 21 
lesions. Therefore, detection of an adrenal mass in patients with active or previous malignancy 22 
requires a careful differential diagnostic work-up. 18F-Fluorodeoxyglucose-positron emission 23 
tomography/computed tomography (18F-FDG-PET/CT) is increasingly used to determine the 24 
malignant potential of adrenal lesions.   25 
We report the case of a 64-year-old man who had a single adrenal metastasis due to non-small-cell 26 
lung carcinoma developing on a pre-existing benign adrenal lesion. This metastasis occurred in a 27 
phase of perceived oncological remission and was detected thanks to 18F-FDG-PET/CT showing a 28 
focal adrenal uptake. Contrast-enhanced computed tomography (CT), performed as part of 29 
oncological follow-up, and MRI with chemical shift sequences did not lead to the correct diagnosis. 30 
The patient underwent laparoscopic adrenalectomy and the pathological evaluation confirmed a lung 31 
carcinoma metastasis. 32 
The present case highlights the peculiarity of the follow-up of adrenal masses in cancer patients and 33 
the primary role of 18F-FDG-PET/CT in the management of such patients. 34 





About 2% of all incidentally detected adrenal masses are of metastatic nature. This percentage rises 37 
to 30-70% in patients affected by an extra-adrenal malignancy [1] . The adrenal gland represents 38 
indeed a frequent site of metastasis, due to its rich sinusoidal vascularization. Lung cancer followed 39 
by breast cancer and melanoma are most likely to spread to the adrenal gland [2] . Rare cases of 40 
collision tumors, defined as the coexistence of two different tumors in an adrenal gland, such as an 41 
adrenal adenoma and an adrenal cancer or a metastatic tumor, have been described [3].  42 
Although no randomized study comparing imaging tests has been performed, non-contrast computed 43 
tomography (CT) is generally considered as the first-line imaging test to make a differential 44 
diagnosis between benign and malignant adrenal masses. Whenever the mass is considered of 45 
indeterminate nature after non-contrast CT, second-line imaging tests, including CT with delayed 46 
contrast media washout, chemical shift MRI, and 18F-FDG-PET/CT, are needed to define the 47 
diagnosis [4]. Once that an adrenal incidentaloma is considered to be a benign lesion after an 48 
appropriate work-up, it is not recommended to pursue a specific follow-up with repeated imaging 49 
studies [4]. The recommendation is based on the very low chance that a benign adrenal lesion may 50 
turn in a malignant one during follow-up [5]. 51 
We report here in a case that represents an exception to this general rule and underlines the 52 
challenges that may arise in the diagnosis of adrenal metastases.   53 
 54 
Case presentation 55 
The patient is a 64-year-old man, ex-smoker (10 cigarettes/day), with an occupational exposure to 56 
silica dust and asbestos and a clinical history of chronic obstructive pulmonary disease and arterial 57 
hypertension. In 2008, a left adrenal nodule was occasionally detected and investigated with 58 
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endocrinological workup and non-contrast CT, which were suggestive for a benign, non-functioning, 59 
adrenal adenoma. The lesion was of 30 mm in size with a density < 0 Hounsfield Units (HU) [Figure 60 
1]. 61 
In August 2015, a squamous cell carcinoma of the upper lobe of the right lung with mediastinal 62 
lymphadenopathy was diagnosed. The patient was treated with chemo- and radiotherapy with 63 
complete disease response and subsequent negative radiological follow-up. 64 
In September 2017, a follow-up total body contrast-enhanced CT scan showed multiple pulmonary 65 
lesions and a slight enlargement of the known left adrenal nodule (37 mm diameter) [Figures 2a and 66 
2b]. Hounsfield Units and morphological characteristics were not reported. Due to the suspect of 67 
disease recurrence a 18F-FDG-PET/CT scan was performed and it showed a focal pathological uptake 68 
in the left adrenal region without relevant uptakes in other sites (absolute SUV value 7.8, 69 
adrenal/liver ratio 3.5) [Figure 2c], while the pulmonary lesions resolved after antibiotic therapy. 70 
The patient was then referred to our outpatient unit. A hormonal workup was negative for 71 
hypercortisolism, primary hyperaldosteronism and catecholamine excess. All the available CT scans 72 
were re-evaluated by an expert radiologist, who confirmed the increase in size (7 mm) and described 73 
the adrenal mass as inhomogeneous with faintly irregular borders. Due to the changed radiological 74 
characteristics an adrenal magnetic resonance imaging (MRI) with chemical shift sequences was 75 
performed but was not conclusive in the differential diagnosis between a lipid-poor adenoma and a 76 
malignant lesion, showing incomplete, inhomogeneous signal intensity loss in out-of-phase 77 
sequences [Figures 3a and 3b].  78 
Following the pathological adrenal uptake at FDG-PET scan, not justified by an autonomous 79 
hormone production, and the undetermined radiological characteristics at MRI the patient underwent 80 
left laparoscopic adrenalectomy with an uneventful course. The pathological exam revealed that the 81 
adrenal parenchyma was completely replaced by squamous carcinoma cells, with typical 82 






Whether most adrenal masses detected in patients affected by extra-adrenal malignancies are of 86 
secondary nature, adrenal metastases are rarely found in non-oncological patients [1]. Therefore, a 87 
history of known extra-adrenal malignancy requires a particular attention to the possibility of an 88 
adrenal metastasis. A new adrenal lesion developing during oncological follow-up should also be 89 
viewed as suspicious.  90 
In clinical practice, the most commonly used imaging techniques to assess the risk of malignancy are: 91 
non-contrast CT, MRI with chemical shift sequences, and 18F-FDG-PET/CT. The recent 92 
ESE/ENSAT guidelines on the management of adrenal incidentalomas recommended non-contrast 93 
CT as the first radiological test [4]. Adrenal lesions that are homogeneous, smaller than 4 cm, with 94 
density < 10 Hounsfield units (HU) are considered benign, lipid-rich adenomas. However, about 30% 95 
of adrenal adenomas are lipid-poor and show an attenuation value > 10 HU that overlaps with 96 
malignant lesions and pheochromocytomas [6-8]. The use of MRI with chemical shift sequences is 97 
based on the typical loss of signal intensity shown by intracellular lipid-rich lesions in out-of-phase 98 
sequences, while lipid-poor adenomas, malignant lesions and pheochromocytomas remain unchanged 99 
[9-11]. In patients with history of extra-adrenal malignancy, the ESE/ENSAT guidelines suggest the 100 
use of 18F-FDG-PET/CT performed as part of oncological follow-up [4]. 18F-FDG-PET/CT has the 101 
advantage of being able to detect malignant adrenal lesions with a low rate of false negatives (mainly 102 
metastases from tumors with low FDG-uptake, i.e. kidney cancer [12]) and a certain rate of false 103 
positives (i.e., functional adenomas [13]) [14]. Routine use of 18F-FDG-PET/CT in patients without 104 
history or suspect of malignancy is currently not recommended, but a recent prospective study 105 
showed that it has an excellent negative predictive value in the characterization of indeterminate 106 
and/or large adrenal masses in non-cancer patients [15].  107 
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In our patient, the contrast-enhanced CT performed during the oncological follow-up reported only a 108 
slight enlargement of the known adrenal lesion and only the radiological revision, requested after the 109 
18F-FDG-PET/CT, showed changes of the lesion’s features. The 18F-FDG-PET/CT was done 110 
primarily for the suspect of pulmonary progression of disease but showed a single, focal uptake of 111 
the known adrenal lesion. Since the mass has been previously recognized as benign, further 112 
diagnostic tests were done. Hormone assessment was unrewarding, and MRI was still compatible 113 
with a lipid-poor adenoma. Our case represents a “real-life” demonstration of the limits of 114 
radiological and functional imaging in defining adrenal masses nature, especially in patients with 115 
known oncological history. These limits have been widely analyzed in a systematic review and meta-116 
analysis [16] which laid the groundwork for the recommendations given by the ESE/ENSAT 117 
guidelines, especially when second-line imaging techniques are used in indeterminate adrenal 118 
masses. Despite the great potential of available radiological and functional imaging, there are not 119 
only difficulties related to the heterogeneity of both benign and malignant adrenal lesions and to the 120 
frequent overlap in imaging features [17], but also the expertise of the single radiologist and clinician 121 
influence the patient’s diagnostic pathway in clinical practice. 122 
In our patient, since radiological and functional imaging were not conclusive in defining the nature of 123 
the adrenal lesion’s changes, a histopathological evaluation was considered essential. The 124 
multidisciplinary team discussion considered the adrenal biopsy  a possible choice, but since we had 125 
a consistent suspicion of malignancy and the patient was in excellent clinical conditions with a 126 
prolonged disease-free interval following oncological treatment of his non-small cell lung cancer 127 
(NSCLC), we decided to be proactive and recommended surgical removal of the adrenal lesion. Our 128 
choice was also supported by the expertise of our surgeon and the notion of a favorable outcome of 129 
patients who underwent removal of solitary adrenal metastases from different cancer types, including 130 




Since the first description of adrenalectomy for isolated metastasis in 1982 [18], many retrospective 132 
series showed a potential benefit in survival in well-selected patients undergoing surgical treatment 133 
[19-26].  134 
In recent years, there is growing evidence in support of use of laparoscopic approach in malignant 135 
adrenal lesions ensuring an adequate oncologic result, in addition to the advantages of mini-invasive 136 
surgery in terms of safety and post-operative recovery [27-30]. Therefore, laparoscopic 137 
adrenalectomy represents the first-choice surgical option in these patients.  138 
Given the low probability that a benign adrenal lesion becomes malignant during follow-up [5], an 139 
active imaging surveillance of adrenal incidentalomas that are characterized to be benign is currently 140 
not recommended [4, 31]. However, oncological patients may represent a possible exception to the 141 
rule because neoplastic cells may be seeded in a pre-existing benign lesion. Whether the coexistence 142 
of a metastasis in an adrenal benign lesion is an incidental occurrence or represents the result of 143 
changes in the local environment that may favor hematogenous metastatization in an adrenal 144 
adenoma is not still clear. In 2014, Untch and colleagues [3] reviewed 11 histopathologically-proved 145 
adrenal collision tumors described in literature. In the last five years other 14 case reports of adrenal 146 
collision tumors have been published [3, 32-51]. The 25 cases are summarized in Table 1. In 18 147 
cases, an adrenal adenoma was present. In 17 cases a malignant component was described, in 6 cases 148 
of primitive adrenal origin, in 11 cases of metastatic nature. 3 cases were lung cancer metastases, one 149 
small cell lung carcinoma (SCLC) and two NSCLC. 150 
 151 
Conclusions 152 
In conclusion, we have reported the development of a solitary adrenal metastasis on a pre-existing 153 
benign adrenal lesion in a patient with a NSCLC in apparent clinical remission. Although oncologists 154 
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and pneumologists, familiar with the way of metastatic spreading of lung carcinoma, are used to 155 
follow up patients with total body CT, this case report highlights the peculiarity of the follow-up of 156 
adrenal masses in cancer patients. While imaging follow-up of adrenal incidentalomas is seldom 157 
recommended [4, 5, 31] any adrenal lesion in a patient with known oncological disease should be 158 
carefully evaluated at any restaging, even if the mass has been previously labelled as benign. This is 159 
of utmost importance when a complete response of the primary cancer has been obtained after 160 
treatment, since the detection of new adrenal metastasis may change the management plan. In this 161 
clinical scenario, 18F-FDG-PET/CT represents a valid tool to guide clinicians in the decision-making 162 
process [52]. 163 
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